2012
DOI: 10.2165/11594930-000000000-00000
|View full text |Cite
|
Sign up to set email alerts
|

Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode

Abstract: Compared with olanzapine, the results suggest that quetiapine is cost effective as a maintenance treatment for bipolar depression.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
70
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 19 publications
(70 citation statements)
references
References 55 publications
0
70
0
Order By: Relevance
“… satisfied the lowest number of quality criteria (49%), the DES model developed by Ekman et al. fulfilled the highest proportion (94%).…”
Section: Resultsmentioning
confidence: 98%
See 2 more Smart Citations
“… satisfied the lowest number of quality criteria (49%), the DES model developed by Ekman et al. fulfilled the highest proportion (94%).…”
Section: Resultsmentioning
confidence: 98%
“…All of the modeling studies in our review had a clear definition of the decision problem, model objectives, and scope. Different modeling approaches were used to address the study question, including one decision tree model , eight cohort‐based Markov models , two DES studies , two publications using the same mathematical model , and two studies that failed to explicitly state their approach or structure . All studies except Klok et al.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Probabilities of discontinuation and relapse to manic, mixed, and depressive episodes were sourced from published meta-analyses [29, 30]. …”
Section: Methodsmentioning
confidence: 99%
“…As in the UK model, probability of discontinuing treatment with the initial drug during periods of disease stability was calculated by applying a risk ratio from a published meta-analysis of clinical trials [34] to an underlying baseline probability of discontinuing on placebo. The placebo discontinuation rates are based on a published discrete-event simulation model for patients with acute bipolar depression [29]. Again, as ASE-treatment discontinuation risk was not available in the meta-analysis, it was assumed that the treatment discontinuation probability for ASE was the same as for OLA (Table 1).…”
Section: Methodsmentioning
confidence: 99%